Release Date: 23/12/15 18:14 Summary: First Supplementary Bidder's Statement Price Sensitive: Yes Download Document 343.53KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%